drugset / Trial / NCT00909610

Ursodiol Tablets 500 mg Under Fasting Conditions

NCT00909610

Phase 1 Completed 80 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to evaluate the comparative bioavailability between Ursodiol 500 mg Tablets (test) and Urso Forte™ 500 mg Tablets (reference) after a single-dose in healthy subjects under fasting conditions.

Timeline

Start
2006-12
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 500 mg

Indications

No indication recorded.